Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA12 | O43570 | 3/20 | 0.52 |
| ▸ | CA2 | P00918 | 3/20 | 0.52 |
| ▸ | CA4 | P22748 | 3/20 | 0.52 |
| ▸ | CA6 | P23280 | 3/20 | 0.52 |
| ▸ | CA5A | P35218 | 3/20 | 0.52 |
| ▸ | CA7 | P43166 | 3/20 | 0.52 |
| ▸ | CA9 | Q16790 | 3/20 | 0.52 |
| ▸ | CA14 | Q9ULX7 | 3/20 | 0.52 |
| ▸ | CA5B | Q9Y2D0 | 3/20 | 0.52 |
| ▸ | F13A1 | P00488 | 2/20 | 0.52 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.52 |
| ▸ | ALOX15 | P16050 | 2/20 | 0.52 |
| ▸ | THPO | P40225 | 2/20 | 0.52 |
| ▸ | CASP2 | P42575 | 2/20 | 0.52 |
| ▸ | MEN1 | O00255 | 1/20 | 0.52 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.52 |
| ▸ | RECQL | P46063 | 1/20 | 0.52 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.52 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.52 |
| ▸ | CA3 | P07451 | 2/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7690028 | 0.98 | CA12 (0.54) | CA12CA2CA4CA6CA5A | |
| Hydrochloric Acid SCHEMBL30087527 | 0.96 | UBE2N (0.56) | CA12CA2CA4CA6CA5A | |
| SCHEMBL7690024 | 0.96 | CA12 (0.50) | CA12CA2CA4CA6CA5A | |
| SCHEMBL30218642 | 0.88 | CA12 (0.43) | CA12CA2CA4CA6CA5A | |
| Spermine SCHEMBL564391 | 0.78 | CA12 (0.77) | CA12CA2CA4CA6CA5A | |
| SCHEMBL13671559 | 0.78 | CA12 (0.54) | CA12CA2CA4CA6CA5A | |
| SCHEMBL25400461 | 0.75 | — | — | |
| Spermidine SCHEMBL30480269 | 0.75 | CA12 (0.78) | CA12CA2CA4CA6CA5A | |
| SCHEMBL14765600 | 0.75 | CA12 (0.50) | CA12CA2CA4CA6CA5A | |
| SCHEMBL14270998 | 0.75 | CA12 (0.56) | CA12CA2CA4CA6CA5A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-110714005-B | Functional microsphere for enriching oxidized nucleic acid and method for enriching oxidized nucleic acid | 青岛大学 | 2022-12-16 | — | — | CN | claimed |
| EP-3604533-A1 | SITE-SPECIFIC DELIVERY OF NUCLEIC ACIDS BY COMBINING TARGETING LIGANDS WITH ENDOSOMOLYTIC COMPONENTS | Arbutus Biopharma Corporation (CA) | 2020-02-05 | — | — | EP | disclosed |
| CN-110564811-A | Method for enriching oxidized nucleic acids | 青岛大学 | 2019-12-13 | — | — | CN | disclosed |
| US-20190048344-A1 | CHEMICAL MODIFICATIONS OF MONOMERS AND OLIGONUCLEOTIDES WITH CYCLOADDITION | ALNYLAM PHARMACEUTICALS INC (US) | 2019-02-14 | — | — | US | disclosed |
| US-20180221494-A1 | SITE-SPECIFIC DELIVERY OF NUCLEIC ACIDS BY COMBINING TARGETING LIGANDS WITH ENDOSOMOLYTIC COMPONENTS | ARBUTUS BIOPHARMA CORPORATION (CA) | 2018-08-09 | — | — | US | disclosed |
| US-9895448-B2 | Site-specific delivery of nucleic acids by combining targeting ligands with endosomolytic components | ARBUTUS BIOPHARMA CORPORATION (CA) | 2018-02-20 | — | — | US | disclosed |
| US-20160367687-A1 | SITE-SPECIFIC DELIVERY OF NUCLEIC ACIDS BY COMBINING TARGETING LIGANDS WITH ENDOSOMOLYTIC COMPONENTS | TEKMIRA PHARMACEUTICALS CORPORATION (CA) | 2016-12-22 | — | — | US | disclosed |
| US-9345780-B2 | Site specific delivery of nucleic acids by combining targeting ligands with endosomolytic components | TEKMIRA PHARMACEUTICALS CORPORATION (CA) | 2016-05-24 | — | — | US | disclosed |
| US-20150203847-A1 | CHEMICAL MODIFICATIONS OF MONOMERS AND OLIGONUCLEOTIDES WITH CYCLOADDITION | ALNYLAM PHARMACEUTICALS INC (US) | 2015-07-23 | — | — | US | disclosed |
| US-8962580-B2 | Chemical modifications of monomers and oligonucleotides with cycloaddition | ALNYLAM PHARMACEUTICALS, INC. (US) | 2015-02-24 | — | — | US | disclosed |
| US-20140256785-A1 | SITE SPECIFIC DELIVERY OF NUCLEIC ACIDS BY COMBINING TARGETING LIGANDS WITH ENDOSOMOLYTIC COMPONENTS | TEKMIRA PHARMACEUTICALS CORPORATION (CA) | 2014-09-11 | — | — | US | disclosed |
| US-8575123-B2 | Site-specific delivery of nucleic acids by combining targeting ligands with endosomolytic components | TEKMIRA PHARMACEUTICALS CORPORATION (CA) | 2013-11-05 | — | — | US | disclosed |
| US-20120035115-A1 | CHEMICAL MODIFICATIONS OF MONOMERS AND OLIGONUCLEOTIDES WITH CYCLOADDITION | ALNYLAM PHARMACEUTICALS, INC. (US) | 2012-02-09 | — | — | US | disclosed |
| EP-2342616-A2 | CHEMICAL MODIFICATIONS OF MONOMERS AND OLIGONUCLEOTIDES WITH CYCLOADDITION | Alnylam Pharmaceuticals Inc. (US) | 2011-07-13 | — | — | EP | disclosed |
| US-20110123520-A1 | SITE-SPECIFIC DELIVERY OF NUCLEIC ACIDS BY COMBINING TARGETING LIGANDS WITH ENDOSOMOLYTIC COMPONENTS | ALNYLAM PHARMACEUTICALS, INC. (US) | 2011-05-26 | — | — | US | disclosed |
| EP-2274425-A2 | SITE-SPECIFIC DELIVERY OF NUCLEIC ACIDS BY COMBINING TARGETING LIGANDS WITH ENDOSOMOLYTIC COMPONENTS | Alnylam Pharmaceuticals Inc. (US) | 2011-01-19 | — | — | EP | disclosed |
| WO-2010039548-A2 | CHEMICAL MODIFICATIONS OF MONOMERS AND OLIGONUCLEOTIDES WITH CYCLOADDITION | ALNYLAM PHARMACEUTICALS, INC. (US) | 2010-04-08 | — | — | WO | disclosed |
| WO-2009126933-A2 | SITE-SPECIFIC DELIVERY OF NUCLEIC ACIDS BY COMBINING TARGETING LIGANDS WITH ENDOSOMOLYTIC COMPONENTS | ALNYLAM PHARMACEUTICALS, INC. (US) | 2009-10-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150203847-A1 | CHEMICAL MODIFICATIONS OF MONOMERS AND OLIGONUCLEOTIDES WITH CYCLOADDITION | DNMT1, LCK, MCTS1 | CA12 2617/4885CA2 3180/4885CA4 2494/4885 |
| US-20190048344-A1 | CHEMICAL MODIFICATIONS OF MONOMERS AND OLIGONUCLEOTIDES WITH CYCLOADDITION | DNMT1, LCK, MCTS1 | CA12 2617/4885CA2 3180/4885CA4 2494/4885 |
| US-20140256785-A1 | SITE SPECIFIC DELIVERY OF NUCLEIC ACIDS BY COMBINING TARGETING LIGANDS WITH ENDOSOMOLYTIC COMPONENTS | HAVCR2, BST2, ANXA6 | CA12 1505/4885CA2 2469/4885CA4 2627/4885 |
| US-20180221494-A1 | SITE-SPECIFIC DELIVERY OF NUCLEIC ACIDS BY COMBINING TARGETING LIGANDS WITH ENDOSOMOLYTIC COMPONENTS | HAVCR2, LNPEP, BST2 | CA12 1365/4885CA2 2296/4885CA4 2459/4885 |
| US-20160367687-A1 | SITE-SPECIFIC DELIVERY OF NUCLEIC ACIDS BY COMBINING TARGETING LIGANDS WITH ENDOSOMOLYTIC COMPONENTS | HAVCR2, LNPEP, BST2 | CA12 1365/4885CA2 2296/4885CA4 2459/4885 |
| US-20110123520-A1 | SITE-SPECIFIC DELIVERY OF NUCLEIC ACIDS BY COMBINING TARGETING LIGANDS WITH ENDOSOMOLYTIC COMPONENTS | HAVCR2, LNPEP, BST2 | CA12 1365/4885CA2 2296/4885CA4 2459/4885 |
| US-20120035115-A1 | CHEMICAL MODIFICATIONS OF MONOMERS AND OLIGONUCLEOTIDES WITH CYCLOADDITION | DNMT1, LCK, MCTS1 | CA12 2617/4885CA2 3180/4885CA4 2494/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.